Riskpilot← Back to searchSign inGet full accessOrbis Medicines ApS
APSActiveCVR 42715646Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 202126 employees
Revenue 2024
DKK -51,6M
+102% vs 2023
EBITDA margin
101.0%
-104% vs 2023
Equity ratio
80.1%
Financial strength
Net profit 2024
DKK -37M
-110% vs 2023
| Revenue | DKK -51,6M | +102% |
| EBITDA | DKK -52,1M | -104% |
| Net profit | DKK -37M | -110% |
| Total assets | DKK 158,6M | +125% |
| Equity | DKK 127M | +84% |
| Employees | 26 | — |
Legal name
Orbis Medicines ApS
CVR number
42715646
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. september 2021
Share capital
DKK 2.849.471
Employees
26 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med formanden for bestyrelsen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af medicinske produkter samt aktiviteter, der efter bestyrelsens skøn er forbundet dermed.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | -15.220 | -25.596 | -51.629 |
| Staff expenses | -140 | -0 | -493 |
| EBITDA | -15.360 | -25.596 | -52.122 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -15.360 | -25.596 | -52.122 |
| Net financials | 899 | 2.093 | 3.597 |
| Profit before tax | -14.461 | -23.503 | -48.526 |
| Tax | -3.411 | -5.865 | -11.505 |
| Net profit | -11.049 | -17.638 | -37.021 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 28.713 | 70.366 | 158.639 |
| Equity | 26.987 | 68.950 | 127.020 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 1.726 | 1.416 | 31.620 |
| Total debt | 1.726 | 1.416 | 31.620 |
EBITDA margin
-5212218800.0%
This company
15.8%
Market median
-32988726682% vs market
20222024
Equity ratio
80.1%
This company
38.2%
Market median
+110% vs market
20222024
Return on equity
-29.1%
This company
18.4%
Market median
-258% vs market
20222024
Net profit margin
-3702093300.0%
This company
8.1%
Market median
-45704855656% vs market
20222024
Asset turnover
-0.33×
This company
1.12×
Market median
-129% vs market
20222024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2021-09-28 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MD Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
SS Management | Management | 2021 | — | — |
JC Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 33.3% | 33.3% | 2024 |
| Individual | 33.3% | 33.3% | 2024 | |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Orbis Medicines ApS Board members of Orbis Medicines ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Døssing | Chief Executive Officer | 0 companies |
| Søren Sylvester Skjærbæk | Management | 0 companies |
| João Carlos Ribas de Almeida | Management | 0 companies |
| Alonso Ricardo Rodriguez | Board of Directors | 0 companies |
| Vanessa Carle | Board of Directors | 0 companies |
| Goran Mikael Dolsten | Chairman | 0 companies |
| Marco Boorsma | Board of Directors | 0 companies |
| Edward Timothy Mathers | Board of Directors | 0 companies |
| Søren Møller | Board of Directors | 0 companies |